Affymax, Inc. Completes Enrollment in PEARL 1, the First of Four Phase 3 Clinical Trials of Hematide(TM) to Treat Anemia in Chronic Renal Failure Patients

PALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in the first of four Phase 3 clinical trials of its lead investigational therapy, Hematide™, which is being evaluated for the treatment of anemia in chronic renal failure patients. PEARL 1 (Phase 3 Evaluation of Hematide for Anemia Correction in Chronic Renal Failure) is fully enrolled with over 475 non-dialysis patients from over 70 sites in the United States.